Cat Allergy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cat Allergy - Pipeline Review, H1 2016', provides an overview of the Cat Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cat Allergy - The report reviews pipeline therapeutics for Cat Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cat Allergy therapeutics and enlists all their major and minor projects - The report assesses Cat Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cat Allergy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cat Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cat Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Cat Allergy - Overview 7 Cat Allergy - Therapeutics under Development by Companies 8 Cat Allergy - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Cat Allergy - Products under Development by Companies 12 Cat Allergy - Companies Involved in Therapeutics Development 13 ALK-Abello A/S 13 Amgen Inc. 14 Biomay AG 15 Circassia Pharmaceuticals Plc 16 Cat Allergy - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 Allergen for Cat Allergy - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Allergen for Cat Allergy - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BM-36 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Epsi-Gam - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 tezepelumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Vaccine for Cat Allergy - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Vaccine for Cat Allergy - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Cat Allergy - Recent Pipeline Updates 35 Cat Allergy - Dormant Projects 38 Cat Allergy - Discontinued Products 39 Cat Allergy - Product Development Milestones 40 Featured News & Press Releases 40 Jan 08, 2015: Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study 40 Feb 25, 2013: Circassia's ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy 40 Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 41 Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology 42 Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 42 Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 43 Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine 43 Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 44 Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Cat Allergy, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Cat Allergy - Pipeline by ALK-Abello A/S, H1 2016 13 Cat Allergy - Pipeline by Amgen Inc., H1 2016 14 Cat Allergy - Pipeline by Biomay AG, H1 2016 15 Cat Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Cat Allergy Therapeutics - Recent Pipeline Updates, H1 2016 35 Cat Allergy - Dormant Projects, H1 2016 38 Cat Allergy - Discontinued Products, H1 2016 39
List of Figures
Number of Products under Development for Cat Allergy, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Targets, H1 2016 18 Number of Products by Stage and Targets, H1 2016 18 Number of Products by Routes of Administration, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 21 Number of Products by Molecule Types, H1 2016 23 Number of Products by Stage and Molecule Types, H1 2016 23
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.